Gerards MC, et al. - This study aimed to compare the effectiveness and safety of add-on treatment with dapagliflozin to placebo in subjects with prednisone-induced hyperglycemia during treatment for acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Compared to placebo, dapagliflozin did not result in better glycemic control in patients with prednisone-induced hyperglycemia during AECOPD.

Methods

• A total of 46 patients hospitalized for an AECOPD were enrolled in a multicenter double-blind randomized controlled study in which add-on treatment with dapagliflozin 10 mg was compared to placebo.
• They measured glycemic control and incidence of hypoglycemia through a blinded subcutaneous continuous glucose measurement device.

Results

• In the dapagliflozin group, subjects spent 54 ± 27.7% of the time in target range (3.9-10 mmol/L) and this was 53.6 ± 23.4% in the placebo group (p=0.96).
• In the dapagliflozin group, mean glucose concentration was 10.1 mmol/L and in the placebo group the value was noted to be 10.4 mmol/L (p=0.66).
• A symptomatic hypoglycemia was reported by 1 patient using dapagliflozin and 2 patients using placebo.
• Compared to placebo, treatment with dapagliflozin was safe and there was no difference in risk of hypoglycemia.